KLRS Stock — Kalaris Therapeutics, Inc.: Metrics

Market overview

2 metrics

Share price

$3.92

Market cap

$93.32M

Price action

19 metrics

Price change (1W)

-6.7%

Price change (30D)

-3.2%

Price change (3M)

-15.7%

Price change (6M)

-58.4%

Price change (YTD)

-53.6%

Price change (1Y)

-3.9%

Trailing year

Price change (5Y)

—

52-week high

$10.98

52-week low

$3.34

Change from 52-week high

-64.3%

Change from 52-week low

+17.4%

Annualized volatility

106.5%

Beta

0.9

RSI (14D)

44.3

Price vs SMA 50

-5.6%

Price vs SMA 200

-39.3%

Avg volume (3M)

251,600

Relative volume

0.3

Average dollar volume

$1.08M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

23.80M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

—

P / book

1.6

reciprocal yield 61.8%

FCF yield

—

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-47.4%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2023-02-15

Profitability

9 metrics

Gross margin

—

Operating margin

-16,182.4%

Trailing 12 months

Net margin

-14,447.9%

Gross profit (TTM)

—

Operating profit (TTM)

−$47.76M

Net income (TTM)

−$44.26M

Trailing 12 months

Diluted EPS (TTM)

$-0.66

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-564.15

Growth

11 metrics

Revenue growth YoY

—

Year over year

Net income growth YoY

—

Revenue (TTM)

—

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+27.2%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-76.7%

Return on assets

-44.5%

Debt / equity

—

Current ratio

11.0

EBITDA (TTM)

—

Free cash flow (TTM)

—

Quick ratio

11.0

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$93.54M

Latest balance sheet

Cash & equivalents

$43.17M

Total assets

$99.54M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$41.02M

Capital expenditures (TTM)

—

R&D (TTM)

$32.87M

SG&A (TTM)

—

Stock compensation (TTM)

$2.19M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

57

13F filer change QoQ

-1

Institutional ownership

75.8%

Short interest

3 metrics

Short interest

1.7%

Latest settlement · 6.2 days to cover

Days to cover

6.2d

Short-squeeze score

54 / 100

Insider activity

2 metrics

Net insider buying (90D)

—

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

KLRS · Kalaris Therapeutics, Inc.

KLRS metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search